A Revolutionary Approach to Early Cancer Detection
CancerIQ, a Black-owned healthcare technology company cofounded by Dr. Olufunmilayo (Funmi) Olopade and her daughter, Feyi Olopade Ayodele, has secured $14 million in funding to advance their mission of using AI technology to detect cancer early.
Addressing Disparities in Cancer Care
CancerIQ’s innovative approach aims to tackle the disparities in cancer care that disproportionately affect underserved communities. By providing personalized risk assessments and tailored care plans, the company is working to bridge the gap in access to crucial cancer screenings and early detection.
“CancerIQ’s vision is to end cancer as we know it by eliminating health disparities and democratizing access to the latest advances in cancer early detection and prevention,” Ayodele said.
Leveraging AI for Precision Health
At the heart of CancerIQ’s platform is the use of AI technology to assess a patient’s cancer risk based on factors such as genetics and family history. By leveraging this cutting-edge technology, the company can connect patients with personalized care plans, ranging from screenings to lifestyle interventions.
Industry Support and Expansion Plans
The $14 million funding round, co-led by Merck Global Health Innovation Fund and Amgen Ventures, underscores the industry’s support for CancerIQ’s vision. With plans to hire 50 new team members, the company is poised to make an even greater impact in the fight against cancer.
“We started by making genetic testing more accessible and connecting patients to the right preventive services at the right time,” Ayodele said.
Bridging Gaps and Democratizing Access
CancerIQ’s mission is not only to detect cancer early but also to bridge the gaps in cancer screening and risk assessment, as highlighted in a recent report from the President’s Cancer Panel.
By democratizing access to advanced detection and prevention methods, the company aims to end cancer disparities and provide equitable care for all.
